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Background: Factors associated with mortality in HIV-infected people in sub-Saharan Africa are widely
reported. However ruralurban disparities and their association with all-cause mortality remain unclear.
Furthermore, commonly used classical Cox regression ignores unmeasured variables and frailty.
Objective: To incorporate frailty in assessing factors associated with mortality in HIV-infected people in rural
and urban South Africa.
Design: Using data from a prospective cohort following 6,690 HIV-infected participants from Soweto (urban)
and Mpumalanga (rural) enrolled from 2003 to 2010; covariates of mortality were assessed by the integrated
nested Laplace approximation method.
Results: We enrolled 2,221 (33%) rural and 4,469 (67%) urban participants of whom 1,555 (70%) and 3,480
(78%) were females respectively. Median age (IQR) was 36.4 (31.044.1) in rural and 32.7 (28.238.1) in
the urban participants. The mortality rate per 100 person-years was 11 (9.712.5) and 4 (3.64.5) in the rural
and urban participants, respectively. Compared to those not on HAART, rural participants had a reduced
risk of mortality if on HAART for 612 (HR: 0.20, 95% CI: 0.100.39) and 12 months (HR: 0.10, 95%
CI: 0.050.18). Relative to those not on HAART, urban participants had a lower risk if on HAART 12
months (HR: 0.35, 95% CI: 0.270.46).
The frailty variance was significant and 1 in rural participants indicating more heterogeneity. Similarly it
was significant but B1 in the urban participants indicating less heterogeneity.
Conclusion: The frailty model findings suggest an elevated risk of mortality in rural participants relative to
the urban participants potentially due to unmeasured variables that could be biological, socioeconomic,
or healthcare related. Use of robust methods that optimise data and account for unmeasured variables could
be helpful in assessing the effect of unknown risk factors thus improving patient management and care in
South Africa and elsewhere.
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S
outh Africa has the highest number of people living
with HIV and the largest antiretroviral treatment
(ART) programme globally (1). Driven by the need
to achieve the millennium development goal of increasing
the number of HIV-infected people accessing treatment
(2), over 2 million people have been started on ARTwith
another half million planned to be started each year.
Mortality in HIV-infected individuals is high (3, 4),
especially prior to ART treatment and while awaiting
ART (5). This is associatedwith highly immunosuppressed
patients with low CD4 counts and high viral loads. While
survival on ART is markedly improved, mortality rates in
the early stages of treatment remain relatively high (4, 6)
signifying the importance of immunosuppression at
the time of ART initiation. Knowledge of risk factors for
mortality is important to improve ART programmes and
to prolong life. Factors associated with mortality in HIV-
infected people in sub-Saharan Africa are widely reported
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with variations. They include CD4 and total lymphocyte
counts, HIV RNA level, WHO and CDC staging, anae-
mia, malnutrition, and gender amongst others (611).
However, prior studies do not specifically report and
compare mortality in rural and urban settings. Further-
more time-to-event methods remain the most commonly
used for the investigation of mortality risk factors parti-
cularly in HIV-infected cohorts (12). Cox proportional
hazards regression analysis, the most popular approach
assumes that the risk of mortality is homogeneous (13),
an assumption that does not often hold (14). In epidemio-
logical studies where some participants are related either
genetically or are from the same family, share some un-
measured covariates, or have multiple recurrence events,
their survival times are not independent due to within -
subject dependency (15). Analysis of such data requires use
of a method that accounts for dependence leading to
heterogeneity such as frailty modelling (1416), an exten-
sion of the Cox regression. Frailty modelling incorporates
within-subject dependency by considering that the indivi-
dual risk of events differs between subjects through
accounting for unmeasured variables (1517). Adjusting
for within-subject correlation and accounting for unmea-
sured variables are some of the advantages of frailty
modelling. Disadvantages include handling of compet-
ing risks and assuming the same risk within a cluster of
unobserved variables.
Understanding the dynamics of mortality in HIV-
infected people in sub-Saharan Africa is important as it
influences patient management and care. As such, assess-
ment of mortality surveillance patterns requires the use
of robust statistical analysis methods that will optimise
findings leading to appropriate policy decisions from
evidence-based research. While current methods are well
established, recent approaches, though more complex,
provide further insight through their ability to model
dependency. Detailed research from sub-Saharan Africa
comparing factors associated with mortality in HIV-
infected people between rural and urban areas using
recently developed advanced methods are limited. Further-
more, those employing methods that account for unmea-
sured variables in this setting are not properly described.
And, more importantly, we hypothesise that they inade-
quately capture uncertainty and are less precise. We there-
fore sought to assess and compare factors associated
with mortality in HIV-infected adults in a large cohort of
participants in a wellness programme in rural and urban
South Africa while accounting for unmeasured variables
in both sites.
Methods
Setting and study population
Data from two South African study sites were used:
Perinatal HIV Research Unit (PHRU) in Soweto and
Tintswalo hospital in Mpumalanga. In this study, parti-
cipants enrolled in PHRU were classified as urban while
those enrolled in Tintswalo were classified as rural. While
both sites provided treatment using the same guideline
from the department of health and similar resources such
as nurses with similar qualifications, Tintswalo hospital
is a primary health centre while the PHRU clinic is a
research centre.
Soweto is an urban area in the city of Johannesburg
in Gauteng, South Africa, with a population greater than
a million people (18). It is in the southwestern part of
Johannesburg where approximately 40% of the popula-
tion resides. While many households are poor with high
unemployment rates, there is a mix of poor and wealthy
residents (18).
Tintswalo hospital is situated in the Bushbuckridge
district of rural South Africa’s northeast with a population
of 541,247 people. Bushbuckridge is among the poorest
areas of South Africa with up to 75% of the population
living in poverty (19).
A nurse-based wellness programme was established in
PHRU and Tinstwalo to provide pre- and post-treatment
care for HIV-infected adults between the years 2003
and 2010. Participants in the study were referred from
voluntary counselling and testing centres, surrounding
clinics, hospital wards, or research programmes. Referrals
for ART were made for those eligible, based on the
South African ART treatment guidelines at the time
(CD4 cell count B200 cells/mm3) (20). Inclusion criteria
were diagnosis of HIV, 18 years of age or older, receiving
primary clinical care at PHRU or Tintswalo clinics and
providing written informed consent. Further study proce-
dures are presented elsewhere (21, 22).
Study questionnaires were administered at baseline
and follow-up visits that occurred every 6 months. Losses
to follow-up were minimised through actively following
up participants by way of telephone calls, letters, and
then home visits. Weight, CD4 counts, creatinine, and
haemoglobin estimations were measured at scheduled
six monthly visits while other investigations were done
according to clinical presentation. To be considered pos-
itive for tuberculosis (TB), subjects had to meet at least
one of the following criteria (21): initiation of multidrug
TB therapy, presence of acid fast bacilli on microscopy or
a biopsy suggestive of TB, mycobacterium culture positive
for acid fast bacilli or Mycobacterium tuberculosis, hospi-
talisation due to TB or cause of death ascribed to TB.
Measures
For this study, the outcome measure was all-cause
mortality, primarily through making contact with the
next of kin. Socio-demographic measures included age,
household income, number of people and rooms in a
household, ever smoked and ever employed. Others were
height and weight for calculating body mass index (BMI),
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HAART status, ever had TB and CD4 counts. BMI was
categorised into three groups using the CDC classifica-
tion: underweight (B18.5), normal (18.524.9), or over-
weight/obese (]25) while CD4 count was categorised
into 0200, 201350, 351500, and 500 cells/mm3.
Ethics
Ethical approval was provided by the Human Research
Ethics Committee of the University of the Witwatersrand.
Statistical analysis
Data were stratified by site. Continuous measures at
enrolment such as age, BMI, and CD4 count were assessed
descriptively by median and interquartile ranges and com-
pared between the two groups using the KruskalWallis
non-parametric test. Frequencies and associated pro-
portions were determined for categorical measures and
compared using the Fishers Exact and Chi–square analy-
sis as appropriate.
Mortality rates (95% confidence interval) per 100
person-years were determined using Poisson regression
modelling by site for different lengths of time pre- and
post-HAART and presented graphically. The Kaplan
Meier test was used to determine differences in surveil-
lance patterns by site.
Factors associated with mortality by site were assessed
using the integrated nested Laplace approximation
(INLA) (23, 24), where univariate and multivariate shared
gamma frailty models were fitted. INLA is a Bayesian
inference technique, computationally efficient due to its
speed relative to existing methods and more accurate
parameter estimates. For the purpose of interpretation,
posterior Bayesian estimates generated from INLA were
exponentiated to determine their approximate hazard
ratios and 95% confidence intervals (25).
INLA accounted for unmeasured variables and allowed
for the comparison of frailty variances between sites.
A significant frailty variance with a value 1 suggests
a higher rate for the event (or shorter survival times)
than would be predicted under the basic Cox model while
B1 suggests a lower rate (longer survival times). Hence,
failure to account for frailty may overestimate or under-
estimate the hazard rate.
Backward selection together with inclusion of plausible
socio-demographic and clinical factors was used to deter-
mine the final multivariate model. Socio-demographic
variables included gender, ever employed, and ever smoked.
Clinical variables included HAARTstatus, BMI, CD4 cell
count, and ever had TB. The most recent information was
used for HAART status while BMI and CD4 cell count
values were considered over time.
A 95% confidence interval excluding one was deter-
mined as significant. Model fit was assessed using the
deviance information criterion.
Multiple imputation (MI) under the missing-at-random
mechanism was used to impute 18% (n1,195) and 11%
(n704) of missing CD4 count and BMI data, respec-
tively (2628). Five imputed datasets reflecting different
scenarios were generated and analysed following the MI
procedure.
Several sensitivity analyses were performed using
INLA. This included assessing factors associated with
mortality overall, pre- and post-HAART. KaplanMeier
plots of time to death by gender, HAART use, CD4
count, WHO staging, and BMI were also fitted. For
participants that were lost to follow-up, their time in the
study up to their last visit was included in the analysis.
All statistical analyses were performed using R and
SAS Enterprise Guide 5.1 under the assumption of a two-
sided test at 5% significance level.
Results
Overall, 6,690 participants were enrolled and followed
up for a cumulative total of 2225.8 and 8185.9 person-
years in the rural (33%) and urban (67%) sites, respectively.
The median (IQR) pre- and post-HAART time in years
was 0.6 (01.9) and 1.1 (0.52.6), respectively. Overall,
75% were women: rural (70%) and urban (78%). The
median age at enrolment was 36.4 (IQR: 31.044.1) and
32.7 (IQR: 28.238.1) years for rural and urban sites,
respectively.
Rural participants were more likely to report a house-
hold income of 5R1,000 per month compared to those
in the urban areas (72.8% vs. 48.5%; pB0.0001). The
proportion not on HAART at the end of the study was
significantly higher in the urban area compared to the
rural area (63.2% vs. 30.0%; pB0.0001) while unemploy-
ment was significantly higher in the rural area (86.7% vs.
70.7%; pB0.0001) relative to the urban areas.
At enrolment, 54% of the rural and 27% of the urban
participants had either started HAART or were already
on HAART. On follow-up, 17 and 10% of rural and
urban participants, respectively, initiated HAART.
The median BMI of urban participants was higher than
that of the rural participants (24.9 vs. 21.0; pB0.0001).
Similarly, the median CD4 count at entry of rural
participants was lower than that in the urban participants
(178 cells/mm3 vs. 303 cells/mm3; pB0.0001, Table 1).
The proportion on HAART for B6 months and with a
most recent CD4 count B200 cells/mm3 was significantly
higher in the urban compared to the rural participants
(76% vs. 59%; pB0.0001). Similarly, urban participants
on HAART for 612 months and with a most recent
CD4 count B200 cells/mm3 were significantly more
than in the rural participants (69% vs. 53%; p0.0004).
The proportion unemployed andwith a CD4 count B200
cells/mm3 was significantly higher in the rural partici-
pants compared to the urban participants (40% vs. 24%;
pB0.0001). The proportion ever with TB in the rural
participants was significantly higher than in the urban
participants (44.8% vs. 25.4%; pB0.0001, Table 2).
Factors associated with mortality in HIV
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Table 1. Participant characteristics at enrolment by site
Rural Urban
Variable Overall (n2,221) Male (n666, 30%) Female (n1,555, 70%) Overall (n4,469) Male (n989, 22%) Female (n3,480, 78%)
Median age (IQR) in years 36.4 (31.044.1) 39.2 (33.348.1) 35.2 (30.042.5) 32.7 (28.238.1) 35.7 (31.541.5) 31.7 (27.437.0)
Age group in years
1825 (%) 216 (9.7) 30 (4.5) 186 (12.0) 672 (15.0) 65 (6.6) 607 (17.4)
2630 (%) 342 (15.4) 72 (10.8) 270 (17.4) 1,117 (25.0) 158 (16.0) 959 (27.6)
3134 (%) 420 (18.9) 111 (16.7) 309 (19.9) 984 (22.0) 222 (22.4) 762 (21.9)
3539 (%) 424 (19.1) 136 (20.4) 288 (18.5) 864 (19.3) 250 (25.3) 614 (17.6)
40 (%) 819 (36.9) 317 (47.6) 502 (32.3) 832 (18.6) 294 (29.7) 538 (15.5)
Median CD4 count (IQR) 178.0 (81.0333.6) 162.0 (69.0289.9) 184.0 (86.0350.6) 303.0 (156.0470.7) 281.0 (142.0443.7) 309.0 (163.0478.2)
CD4 categories
0200 (%) 1,235 (55.6) 398 (59.8) 837 (53.8) 1,474 (33.0) 367 (37.1) 1,107 (31.8)
201350 (%) 472 (21.3) 144 (21.6) 328 (21.1) 1,102 (24.7) 241 (24.4) 861 (24.7)
351500 (%) 284 (12.8) 75 (11.3) 209 (13.4) 915 (20.5) 190 (19.2) 725 (20.8)
500 (%) 230 (10.4) 49 (7.4) 181 (11.6) 978 (21.9) 191 (19.3) 787 (22.6)
Median BMI (IQR) 21.0 (17.925.0) 19.9 (17.223.4) 21.4 (18.425.8) 24.9 (20.729.2) 22.5 (18.226.4) 25.6 (21.430.0)
BMI
Underweight (%) 638 (29.0) 241 (36.9) 397 (25.7) 594 (13.4) 240 (24.8) 354 (10.2)
Normal (%) 987 (44.9) 299 (45.7) 688 (44.6) 1,612 (36.4) 393 (40.6) 1,219 (35.2)
Obese/overweight (%) 572 (26.0) 114 (17.4) 458 (29.7) 2,226 (50.2) 336 (34.7) 1,890 (54.6)
Median crowding index (IQR) 1.5 (1.02.3) 1.3 (0.82.0) 1.6 (1.02.5) 1.5 (1.02.3) 1.0 (1.02.0) 1.5 (1.02.5)
Median household income (IQR)
in Rands
600.0 (189.81010.0) 780.0 (50.01500.0) 500.0 (190.0974.7) 1080.0 (500.02130.0) 1200.0 (600.02400.0) 1020.0 (500.02020.0)
Household income
5R1,000 (%) 1,516 (72.8) 423 (67.4) 1,093 (75.2) 2,161 (48.5) 453 (45.9) 1,708 (49.2)
R1,001R5,000 (%) 528 (25.4) 193 (30.7) 335 (23.1) 2,092 (46.9) 487 (49.3) 1,605 (46.3)
R5,000 (%) 37 (1.8) 12 (1.9) 25 (1.7) 203 (4.6) 47 (4.8) 156 (4.5)
BMI, body mass index; HAART, highly active antiretroviral therapy; TB, tuberculosis.
Crowding index is the number of people divided by the number of rooms in a household; household income refers to household monthly income; for household income, 1USD was
equivalent to R7 at the time of the study.
K
e
n
n
e
d
y
N
.
O
tw
o
m
b
e
e
t
a
l.
4(p
a
g
e
n
u
m
b
e
r
n
o
t
fo
r
c
ita
tio
n
p
u
rp
o
s
e
)
C
ita
tio
n
:
G
lo
b
H
e
a
lth
A
c
tio
n
2
0
1
4
,
7
:
2
5
4
8
8
-
h
ttp
://d
x.d
o
i.o
rg
/1
0
.3
4
0
2
/g
h
a
.v7
.2
5
4
8
8
Overall, 566 (8%) of the participants died during
follow-up: 11 and 7% in rural and urban sites, respec-
tively (pB0.0001). Of these, majority were females (63%
rural vs. 69% urban; p0.1952). Overall, the mortality
rate per 100 person-years in rural sites was higher at 11
(95% CI: 9.712.5) compared to urban sites at 4 (95%
CI: 3.64.5). In the first 6 months, 48% of rural partici-
pants had died while 51% of the deaths in the urban site
occurred after 12 months. Mortality rates per 100 person-
years while on HAART were 11 (95% CI: 8.714.0) and
7 (95% CI: 5.98.3) for rural and urban participants,
respectively. When taking HAART, majority of the
deaths in the rural site occurred within the first 3 months
of treatment initiation (49%) whereas they occurred after
12 months in the urban site (44%). Further description
of those who died pre- and post-treatment in the two
sites by CD4 category and BMI is presented in Table 3.
Relative to the urban participants, mortality rates in the
rural participants was higher (Fig. 1).
In the rural participants, being on HAART for 612
months (HR: 0.20, 95% CI: 0.100.39) and 12 months
(HR: 0.10, 95% CI: 0.050.18) relative to no HAART
was protective after adjusting for CD4 count (Table 4).
However, underweight BMI compared to normal BMI
was associated with a higher risk of mortality (HR: 1.74,
95% CI: 1.062.85).
Being on HAART for B6 months (HR: 4.48, 95% C:
3.06.56) and 612 months (HR: 2.39, 95% CI: 1.60
3.47) compared to no HAART was associated with an
elevated risk of mortality in the urban participants after
adjusting for CD4 count, employment, smoking, and TB
history. However, those with overweight/obese BMI (HR:
0.73, 95% CI: 0.560.90) had a significantly lower risk of
mortality compared to those with normal BMI.
The estimated frailty variances were statistically sig-
nificant for rural and urban sites; 5.65 (95% CI: 4.50
7.19) and 5.4105 (95% CI: 1.5105  8.0104)
respectively.
Discussion
In sub-Saharan Africa where the burden of HIV is the
greatest, research on factors associated with all-cause
mortality in HIV-infected cohorts has widely been done.
However, research on risk factors using advancedBayesian
methods such as INLA that incorporate unmeasured
variables is limited (23, 24). Common protective factors
against mortality included HAART use for 12 months
and CD4 count above 200 cells/mm3 while underweight
BMI was positively associated with mortality. Even with
differences between the rural and urban participants, the
hazard rates were often in the same direction.
While both frailty variances were significant, our
findings show that the frailty variance for participants
in the rural site was higher than that of the urban. This
suggests important unmeasured variables relevant to par-
ticipants in the rural site may not have been considered
(as the variance was 1) signifying more heterogeneity
(variability). In contrast, the variance for participants in
the urban site was B1 signifying less heterogeneity and
probably that the model accounted for most of the
important variables. Available literature on covariates of
mortality relies on classical statistical methods that do
Table 2. Distribution of HAART status, employment, smoking, and TB by site
Rural Urban
Variable
Overall
(n2,221)
Male
(n666, 30%)
Female
(n1,555, 70%)
Overall
(n4,469)
Male
(n989, 22%)
Female
(n3,480, 78%)
Time on HAART
No HAART (%) 666 (30.0) 174 (26.1) 492 (31.6) 2,826 (63.2) 555 (56.1) 2,271 (65.3)
B6 months (%) 468 (21.0) 153 (23.0) 315 (20.3) 356 (8.0) 108 (10.9) 248 (7.1)
612 months (%) 434 (20.0) 133 (20.0) 301 (19.4) 178 (4.0) 35 (3.5) 143 (4.1)
12 months (%) 653 (29.0) 206 (30.9) 447 (28.7) 1,109 (24.8) 291 (29.5) 818 (23.5)
Ever employed
Yes (%) 296 (13.3) 143 (21.5) 153 (9.8) 1,309 (29.3) 400 (40.4) 909 (26.1)
No (%) 1,925 (86.7) 523 (78.5) 1,402 (90.2) 3,160 (70.7) 589 (59.6) 2,571 (73.9)
Ever smoked
Yes (%) 358 (16.1) 295 (44.3) 63 (4.1) 1,284 (28.7) 706 (71.4) 578 (16.6)
No (%) 1,863 (83.9) 371 (55.7) 1,492 (95.9) 3,185 (71.3) 283 (28.6) 2,902 (83.4)
Ever had TB
Yes (%) 995 (44.8) 350 (52.6) 645 (41.5) 1,134 (25.4) 313 (31.6) 821 (23.6)
No (%) 1,226 (55.2) 316 (47.4) 910 (58.5) 3,335 (74.6) 676 (68.4) 2,659 (76.4)
The most recent value is provided for time on HAART.
Factors associated with mortality in HIV
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not account for unmeasured variables (12). Potential
unmeasured variables include 1) biological factors such
as undiagnosed TB and/or other opportunistic infec-
tions such as cryptococcosis, 2) socio-economic factors
that were not included in the data collection process,
3) healthcare-related factors, 4) adherence to HAART
medication, and 5) cultural and religious beliefs. A study
from Portugal assessed predictors of mortality in HIV-
associated hospitalisations, and through frailty modelling,
it was shown how unmeasured variables in the form of
quality in healthcare in different hospitals affected mor-
tality (17). Hence, an assessment that allows for the use of
a mixed methods approach may provide an opportunity
for further insight of the unmeasured variables that may
qualify as risk factors.
Underweight BMI was associated with mortality in
both rural and urban areas with a slightly higher hazard
in the urban group. Our findings concur with others
from previous studies (5, 21, 29). While overweight or
obese BMI was not associated with mortality in rural
participants, it was associated with decreased mortality in
the urban participants. Previous studies have shown that
overweight or obese BMI reduces the risk of mortality
(21). The proportion of participants with underweight
BMIwas higher in the rural groupwhile that of overweight
or obese participants was higher in the urban group
Table 3. Characteristics of those who died
Rural Urban
Variable Overall Male Female Overall Male Female
Total deaths 242 88 154 324 101 223
Mortality rate per 100 person-years (95% CI) 11 (9.712.5) 14 (11.417.3) 10 (8.511.7) 4 (3.64.5) 6 (4.97.3) 3 (2.63.4)
Time to death in months
03 (%) 76 (31.5) 30 (34.1) 46 (30.1) 38 (12.1) 17 (17.7) 21 (9.6)
36 (%) 40 (16.6) 16 (18.2) 24 (15.7) 47 (15.0) 16 (16.7) 31 (14.2)
69 (%) 32 (13.3) 10 (11.4) 22 (14.4) 36 (11.5) 9 (9.4) 27 (12.4)
912 (%) 26 (10.8) 10 (11.4) 16 (10.5) 27 (8.6) 5 (5.2) 22 (10.1)
12 (%) 67 (27.8) 22 (25) 45 (29.4) 166 (52.9) 49 (51) 117 (53.7)
CD4 categories
0200 (%) 167 (69.0) 59 (67.0) 108 (70.1) 195 (60.2) 66 (65.3) 129 (57.8)
201350 (%) 35 (14.5) 11 (12.5) 24 (15.6) 69 (21.3) 18 (17.8) 51 (22.9)
351500 (%) 24 (9.9) 11 (12.5) 13 (8.4) 36 (11.1) 11 (10.9) 25 (11.2)
500 (%) 16 (6.6) 7 (8.0) 9 (5.8) 24 (7.4) 6 (5.9) 18 (8.1)
BMI
Underweight (%) 109 (45.2) 41 (46.6) 68 (44.7) 75 (23.6) 34 (35.1) 41 (18.6)
Normal (%) 95 (39.6) 37 (42.0) 58 (38.2) 126 (39.6) 40 (41.2) 86 (38.9)
Overweight/obese (%) 36 (15.0) 10 (11.4) 26 (17.1) 117 (36.8) 23 (23.7) 94 (42.5)
Deaths on HAART 68 31 37 133 52 81
Mortality rate per 100 person-years (95% CI) 11 (8.714.0) 15 (10.521.3) 9 (6.512.4) 7 (5.98.3) 9 (6.911.8) 6 (4.87.5)
Time to death in months
03 (%) 33 (48.5) 15 (48.4) 18 (48.6) 21 (16.4) 10 (20.4) 11 (13.9)
36 (%) 12 (7.6) 5 (16.1) 7 (18.9) 17 (13.3) 8 (16.3) 9 (11.4)
69 (%) 9 (13.2) 3 (9.7) 6 (16.2) 18 (14.1) 6 (12.2) 12 (15.2)
912 (%) 4 (5.9) 2 (6.5) 2 (5.4) 13 (10.2) 2 (4.1) 11 (13.9)
12 (%) 10 (14.7) 6 (19.4) 4 (10.8) 59 (46.1) 23 (46.9) 36 (45.6)
CD4 categories
0200 (%) 43 (63.2) 19 (16.3) 24 (64.9) 86 (64.7) 39 (75.0) 47 (58.0)
201350 (%) 11 (6.2) 3 (9.7) 8 (21.6) 23 (17.3) 6 (11.5) 17 (21.0)
351500 (%) 9 (13.2) 6 (19.4) 3 (8.1) 13 (9.8) 3 (5.8) 10 (12.3)
500 (%) 5 (7.4) 3 (9.7) 2 (5.4) 11 (8.3) 4 (7.7) 7 (8.6)
BMI
Underweight (%) 25 (37.3) 13 (41.9) 12 (33.3) 30 (22.9) 19 (38.0) 11 (13.6)
Normal (%) 24 (35.8) 9 (29.0) 15 (41.7) 48 (36.6) 21 (42.0) 27 (33.3)
Overweight/Obese (%) 18 (26.9) 9 (29.0) 9 (25.0) 53 (40.5) 10 (20.0) 43 (53.1)
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suggesting differences in nutrition between the two groups.
It may also be that the use of HAART mediated in the
lack of association between mortality and overweight or
obese BMI in the rural participants.
Higher, most recent CD4 count was protective in both
groups as similarly reported in previous studies (30, 31).
However at enrolment, rural participants had a lower
median CD4 count that qualified them to initiate therapy
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Fig. 1. Survival and mortality rate plots by site. a) displays the cumulative probability of death by site in the cohort of HIV-
infected people in South Africa. b) is a plot of mortality rates during follow-up by site showing the period prior to initiating
HAART to post-HAART.
Table 4. Factors associated with mortality in rural and urban South Africa
Rural Urban
Univariate Multivariate Univariate Multivariate
Variable HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Gender
Female vs. male 0.69 (0.451.1) 0.78 (0.481.27) 0.53 (0.420.67) 1.09 (0.801.44)
Time on HAART
B6 months vs. No HAART 1.12 (0.562.22) 1.16 (0.622.16) 17.25 (11.7424.78) 4.48 (3.06.56)
612 months vs. No HAART 0.17 (0.080.37) 0.20 (0.100.39) 7.20 (4.8910.35) 2.39 (1.603.47)
12 months vs. No HAART 0.10 (0.050.20) 0.10 (0.050.18) 1.03 (0.801.32) 0.35 (0.270.46)
BMI
Underweight vs. normal 2.20 (1.403.24) 1.74 (1.062.85) 4.29 (3.265.62) 2.49 (1.873.11)
Overweight/obese vs. normal 0.55 (0.300.98) 0.61 (0.311.16) 0.55 (0.420.71) 0.73 (0.560.90)
CD4 Count (cells/mm3)
201350 vs. 0200 0.26 (0.110.56) 0.25 (0.130.47) 0.19 (0.140.24) 0.22 (0.160.29)
351500 vs. 0200 0.49 (0.201.08) 0.44 (0.210.89) 0.09 (0.060.13) 0.11 (0.070.17)
500 vs. 0200 0.25 (0.080.66) 0.22 (0.090.53) 0.04 (0.020.08) 0.05 (0.030.09)
Ever employed
No vs. Yes 0.95 (0.531.83) 1.13 (0.582.24) 2.03 (1.552.70) 1.87 (1.422.48)
Ever smoked
Yes vs. No 0.99 (0.561.56) 2.07 (1.662.59) 1.37 (1.041.79)
Ever had TB
Yes vs. No 1.66 (1.102.47) 1.55 (0.982.46) 2.84 (2.293.54) 2.76 (2.193.48)
Bold entries represent significant values.
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as per the treatment guidelines at the time. As in many
treatment programmes across sub-Saharan Africa, first
time testers often present for care with low CD4 count.
Previous studies have underscored the relationship be-
tween treatment initiation, low CD4 count, and early
mortality (3235).
Those on treatment for 6 months had a lower risk
of mortality in the rural participants compared to 12
months in the urban participants. Among those on
treatment for 612 months in the urban participants,
a greater proportion had a most recent CD4 count B200
cells/mm3. Findings from prior research show an elevated
risk of early mortality especially in immunocompromised
patients in the early period of treatment (4, 9, 34, 36, 37).
The high mortality rate in urban participants may be due
to late initiation of treatment leading to advanced
HIV disease. Furthermore, the association between late
initiation of treatment and low CD4 count is well esta-
blished. It may also be that mortality was accelerated
in this group by opportunistic infections that were not
identified in time including undiagnosed and untreated
TB. TB remains the most common opportunistic infec-
tion diagnosed in HIV-infected people.
Unemployed urban participants had a higher risk of
mortality, a finding that concurs with previous research
(3841). HIV care was provided at no cost in both sites
irrespective of their employment status. It maybe that
mortality is affected by differential access to care in
urban participants. Other studies have shown that mor-
tality could be affected by poor social situations such
as unemployment, poor housing, and social isolation.
Furthermore, these factors may influence one’s health
negatively (38, 39).
There was an association between ever suffering from
TB and mortality in participants from the urban site.
Contrary to our findings, a previous study fromDurban in
South Africa found no association (36). TB is a common
opportunistic infection in HIV-infected individuals and
its association with mortality is indisputable (21, 37, 42).
Since urban participants were significantly more likely
to have CD4 counts B200 cells/mm3 up to 12 months on
HAART, it may be that they are immune-compromised
and more susceptible to opportunistic infections, such as
TB, and early mortality.
Some variables such as employment were self-reported
and may have been influenced by social desirability bias.
Using cumulative variables such as ‘ever smoking’ or
‘ever employed’ may lead to misclassification given the
fact that it is the cumulative, rather than the instanta-
neous. While all attempts were made to collect and report
all measures, there were some missing values that were
estimated by MIs which may have introduced some bias.
Some deaths may have been misclassified since some
participants were lost to follow-up and reasons for loss
to follow-up were not systematically recorded. However,
an advantage of our study was the large sample size and
the use of a Bayesian frailty survival model that accounts
for unmeasured factors.
Conclusion
Our findings suggest that using robust advanced statis-
tical analysis methods may provide further insight to risk
factors for mortality. Furthermore, and where appropri-
ate, a mixture of methods involving both quantitative and
qualitative approaches could be employed allowing for
further understanding of the unmeasured variables. Such
an approach is likely to inform HIV care managers and
policy makers of important factors for which interven-
tions could be developed or existing ones enhanced to
improve patient management and care. Any such inter-
ventions should alleviate ruralurban healthcare dispa-
rities not only in South Africa but also in other countries
with similar experiences. Interventions should specifically
help in alleviating the challenges faced by rural commu-
nities in accessing care.
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